• 1
    Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. J Am Med Assoc 2011; 305: 2295303.
  • 2
    Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 32740.
  • 3
    Skates SJ, Menon U, MacDonaold N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21: 206s210s.
  • 4
    Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113: 775782.
  • 5
    Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clin Trials 2000; 21(6 Suppl): Suppl-309S.
  • 6
    Etzioni R, Self SG. On the catch-up time method for analyzing cancer screening trials. Biometrics 1996; 51: 3143.
  • 7
    Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010; 37: 20215.
  • 8
    Stratton JF, Pharoah P, Tidy JA, et al. An analysis of ovarian tumor diameter and survival. Int J Gynecol Cancer 2000; 10: 44951.
  • 9
    Menon U, Kalsi J, Jacobs I. The UKCTOCS experience–reasons for hope? Int J Gynecol Cancer 2012; 22: S18S20.